Cytokinetics Inc

Common Name
Cytokinetics
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
498
Ticker
CYTK
Exchange
NASDAQ/NGS
Description
Cytokinetics, Incorporated is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative muscle activators and inhibitors. Its primary mission is to ad...

Cytokinetics's GHG Emissions Data Preview

In 2024, Cytokinetics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Cytokinetics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 2
Market-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Location-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Data

Verified Sources Behind Cytokinetics’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Cytokinetics’s data sources below and access millions more through our Disclosure Search.

a. Cytokinetics's Corporate Responsibility Report (CRR) 2024
a. Cytokinetics's Corporate Responsibility Report (CRR) 2024

Insights into Cytokinetics's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Cytokinetics amounted to 1,254 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Cytokinetics decreased by 14.05%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a

Cytokinetics's Scope 1 Emissions Over Time

2022202320240200400600800tCO2e-34%-43%
  • Total Scope 1
  • Year-over-Year Change

What are Cytokinetics's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Cytokinetics were 242 metric tons of CO₂ equivalent (tCO₂e). a

Has Cytokinetics reduced its Scope 1 emissions over time?

Since 2022, Cytokinetics's Scope 1 emissions have decreased by 62.31%, reflecting a declining long-term trend in Scope 1 emissions over time. a

Compared to the previous year (2023), Cytokinetics's Scope 1 emissions decreased by 42.52%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a

What are Cytokinetics's Scope 2 emissions?

In 2024, Cytokinetics reported Scope 2 greenhouse gas (GHG) emissions of 540 tCO₂e using the market-based method and 1,012 tCO₂e using the location-based method. a

Has Cytokinetics reduced its Scope 2 emissions over time?

Since 2022, Cytokinetics's Scope 2 greenhouse gas (GHG) emissions ( Location-Based) have increased by 21.93%, reflecting a rising long-term trend in Scope 2 emissions over time. a

Compared to the previous year (2023), Cytokinetics's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Cytokinetics 's emissions have plateaued with no significant change in its energy consumption footprint. a

What methodology does Cytokinetics use for Scope 2 reporting?

In 2024, Cytokinetics reported its Scope 2 emissions using the market-based method and using the location-based method. a

Cytokinetics's Scope 2 Emissions Over Time

20222023202403006009001.2 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Cytokinetics’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Cytokinetics reported Scope 1 greenhouse gas (GHG) emissions of 242 tCO₂e and total revenues of USD 18 millions. This translates into an emissions intensity of 13.1 tCO₂e per millions USD. a

Cytokinetics's Scope 1 Emissions Intensity Compared to Peers

505005,00020,000200,000Scope 1 Emissions (tCO2e)101005005,00050,000Revenues (Millions of USD)AIncyteYear: 2024Scope 1: 9,576 tCO2eRevenue: $M 4,241Scope 1 Intensity: 2.26 tCO2e/$MBio-TechneYear: 2023Scope 1: 3,001 tCO2eRevenue: $M 1,137Scope 1 Intensity: 2.64 tCO2e/$MInsmedYear: 2024Scope 1: 1,666 tCO2eRevenue: $M 364Scope 1 Intensity: 4.58 tCO2e/$MLegend BiotechYear: 2024Scope 1: 769 tCO2eRevenue: $M 627Scope 1 Intensity: 1.23 tCO2e/$MFrontage HoldingsYear: 2023Scope 1: 2,883 tCO2eRevenue: $M 2,027Scope 1 Intensity: 1.42 tCO2e/$MRegeneron PharmaceuticalsYear: 2024Scope 1: 80,300 tCO2eRevenue: $M 14,202Scope 1 Intensity: 5.65 tCO2e/$MHalozyme TherapeuticsYear: 2024Scope 1: 1,348 tCO2eRevenue: $M 1,015Scope 1 Intensity: 1.33 tCO2e/$MModernaYear: 2023Scope 1: 11,240 tCO2eRevenue: $M 6,754Scope 1 Intensity: 1.66 tCO2e/$MSarepta TherapeuticsYear: 2023Scope 1: 3,428 tCO2eRevenue: $M 1,243Scope 1 Intensity: 2.76 tCO2e/$MTeleflexYear: 2024Scope 1: 16,256 tCO2eRevenue: $M 3,047Scope 1 Intensity: 5.33 tCO2e/$MMerit Medical SystemsYear: 2023Scope 1: 3,072 tCO2eRevenue: $M 1,257Scope 1 Intensity: 2.44 tCO2e/$MSotera HealthYear: 2023Scope 1: 39,206 tCO2eRevenue: $M 1,049Scope 1 Intensity: 37.36 tCO2e/$MAAAmneal PharmaceuticalsYear: 2024Scope 1: 40,500 tCO2eRevenue: $M 2,794Scope 1 Intensity: 14.50 tCO2e/$MAlignment HealthcareYear: 2023Scope 1: 131 tCO2eRevenue: $M 1,824Scope 1 Intensity: 0.07 tCO2e/$MAlnylam PharmaceuticalsYear: 2024Scope 1: 3,832 tCO2eRevenue: $M 2,248Scope 1 Intensity: 1.70 tCO2e/$MZimmer Biomet HoldingsYear: 2024Scope 1: 10,191 tCO2eRevenue: $M 7,679Scope 1 Intensity: 1.33 tCO2e/$MDaVitaYear: 2024Scope 1: 54,485 tCO2eRevenue: $M 12,815Scope 1 Intensity: 4.25 tCO2e/$MBioMarin PharmaceuticalYear: 2022Scope 1: 14,000 tCO2eRevenue: $M 2,096Scope 1 Intensity: 6.68 tCO2e/$MIonis PharmaceuticalsYear: 2024Scope 1: 2,616 tCO2eRevenue: $M 705Scope 1 Intensity: 3.71 tCO2e/$MHologicYear: 2024Scope 1: 7,050 tCO2eRevenue: $M 4,030Scope 1 Intensity: 1.75 tCO2e/$MVertex PharmaceuticalsYear: 2024Scope 1: 8,976 tCO2eRevenue: $M 11,020Scope 1 Intensity: 0.81 tCO2e/$MCytokineticsYear: 2024Scope 1: 242 tCO2eRevenue: $M 18Scope 1 Intensity: 13.10 tCO2e/$M

How does Cytokinetics's GHG emissions intensity compare to its peers?

In 2024, Cytokinetics reported a Scope 1 emissions intensity of 13.1 tCO₂e per millions USD. Compared to the peer group median of 2.44 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a

Where does Cytokinetics rank on GHG emissions intensity within its industry?

In 2024, Cytokinetics ranked 20 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a

This places Cytokinetics among the least efficient performers, with one of the highest emissions intensities in its sector. a

Want Full Access to Cytokinetics's GHG Emissions Dataset?
Sign Up